Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Moskowitz, Alison J  [Clear All Filters]
2024
Driessen J, de Wit F, Herrera AF, Zinzani PLuigi, Lacasce AS, Cole PD, Moskowitz CH, Garcia-Sanz R, Fuchs M, Mueller H, et al. Brentuximab Vedotin and Chemotherapy in Relapsed/Refractory Hodgkin Lymphoma: a Propensity Score Matched Analysis. Blood Adv. 2024.
Moskowitz AJ, Stuver RN, Horwitz SM. Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs). Blood. 2024.
2023
Stuver R, Horwitz SM, Advani RH, Vose JM, Lee HJu, Mehta-Shah N, Zain JM, Haverkos B, Lechowicz MJo, Moskowitz AJ, et al. Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma. Br J Haematol. 2023.
Epstein-Peterson ZD, Drill E, Aypar U, Batlevi CLee, Caron P, Dogan A, Drullinsky P, Gerecitano J, Hamlin PA, Ho C, et al. Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation. Haematologica. 2023.
2022
Stuver R, Epstein-Peterson ZD, Johnson WT, Khan N, Lewis N, Moskowitz AJ, Sauter CS, Horwitz S. Current Treatment of Peripheral T-cell Lymphoma. Oncology (Williston Park). 2022;36(5):293-305.
2019
Moskowitz AJ. Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma. J Oncol Pract. 2019;15(3):137-143.
2018
Delea TE, Sharma A, Grossman A, Eichten C, Fenton K, Josephson N, Richhariya A, Moskowitz AJ. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. J Med Econ. 2018:1-25.
Ghione P, Moskowitz AJ, De Paola NEK, Horwitz SM, Ruella M. Novel Immunotherapies for T Cell Lymphoma and Leukemia. Curr Hematol Malig Rep. 2018.